CN117362199A - 一种Fmoc-4-Aph(Trt)-OH的1/2三苯甲醇化物及其制备方法 - Google Patents
一种Fmoc-4-Aph(Trt)-OH的1/2三苯甲醇化物及其制备方法 Download PDFInfo
- Publication number
- CN117362199A CN117362199A CN202311299760.2A CN202311299760A CN117362199A CN 117362199 A CN117362199 A CN 117362199A CN 202311299760 A CN202311299760 A CN 202311299760A CN 117362199 A CN117362199 A CN 117362199A
- Authority
- CN
- China
- Prior art keywords
- fmoc
- trt
- aph
- solvent
- trityl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 trityl alcohol compound Chemical class 0.000 title claims abstract description 11
- 238000002360 preparation method Methods 0.000 title abstract description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 33
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims abstract description 25
- 238000000034 method Methods 0.000 claims abstract description 20
- MEUCPCLKGZSHTA-XYAYPHGZSA-N degarelix Chemical compound C([C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CC=1C=CC(NC(=O)[C@H]2NC(=O)NC(=O)C2)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(NC(N)=O)C=C1 MEUCPCLKGZSHTA-XYAYPHGZSA-N 0.000 claims abstract description 15
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims abstract description 15
- 108010052004 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide Proteins 0.000 claims abstract description 14
- 229960002272 degarelix Drugs 0.000 claims abstract description 13
- 238000001953 recrystallisation Methods 0.000 claims abstract description 13
- 239000012454 non-polar solvent Substances 0.000 claims abstract description 6
- 239000002798 polar solvent Substances 0.000 claims abstract description 6
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims abstract description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 24
- 239000002904 solvent Substances 0.000 claims description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 15
- 239000000047 product Substances 0.000 claims description 11
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 8
- 230000015572 biosynthetic process Effects 0.000 claims description 8
- 239000012043 crude product Substances 0.000 claims description 8
- 238000003786 synthesis reaction Methods 0.000 claims description 8
- 238000001816 cooling Methods 0.000 claims description 6
- 239000013078 crystal Substances 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- 239000000243 solution Substances 0.000 claims description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 4
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 claims description 4
- 229940011051 isopropyl acetate Drugs 0.000 claims description 4
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 4
- LZTRCELOJRDYMQ-UHFFFAOYSA-N triphenylmethanol Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(O)C1=CC=CC=C1 LZTRCELOJRDYMQ-UHFFFAOYSA-N 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000003960 organic solvent Substances 0.000 claims description 3
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-Lutidine Substances CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 claims description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 2
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims description 2
- 239000011259 mixed solution Substances 0.000 claims description 2
- 239000003208 petroleum Substances 0.000 claims description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 2
- 239000002994 raw material Substances 0.000 abstract description 10
- 239000012535 impurity Substances 0.000 abstract description 7
- 239000007858 starting material Substances 0.000 abstract description 7
- 206010060862 Prostate cancer Diseases 0.000 abstract description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract description 2
- 239000012830 cancer therapeutic Substances 0.000 abstract 1
- 238000000354 decomposition reaction Methods 0.000 abstract 1
- 239000000758 substrate Substances 0.000 abstract 1
- 230000002194 synthesizing effect Effects 0.000 abstract 1
- 229940126585 therapeutic drug Drugs 0.000 abstract 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical group CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 30
- 239000007787 solid Substances 0.000 description 25
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 20
- 238000001914 filtration Methods 0.000 description 11
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 10
- 235000019341 magnesium sulphate Nutrition 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 238000001035 drying Methods 0.000 description 8
- 238000003756 stirring Methods 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000012044 organic layer Substances 0.000 description 6
- JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 6
- 239000012295 chemical reaction liquid Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 238000000967 suction filtration Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 239000012065 filter cake Substances 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 230000001376 precipitating effect Effects 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 238000001291 vacuum drying Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 3
- 238000001226 reprecipitation Methods 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- JYUTZJVERLGMQZ-AREMUKBSSA-N (2r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-naphthalen-2-ylpropanoic acid Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)N[C@@H](C(=O)O)CC1=CC=C(C=CC=C2)C2=C1 JYUTZJVERLGMQZ-AREMUKBSSA-N 0.000 description 1
- JQLPMTXRCLXOJO-OAQYLSRUSA-N (2r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-pyridin-3-ylpropanoic acid Chemical compound C([C@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C1=CC=CN=C1 JQLPMTXRCLXOJO-OAQYLSRUSA-N 0.000 description 1
- QWXZOFZKSQXPDC-LLVKDONJSA-N (2r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@H](C)C(O)=O)C3=CC=CC=C3C2=C1 QWXZOFZKSQXPDC-LLVKDONJSA-N 0.000 description 1
- CQPNKLNINBUUOM-JOCHJYFZSA-N (2r)-3-(4-chlorophenyl)-2-(9h-fluoren-9-ylmethoxycarbonylamino)propanoic acid Chemical compound C([C@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C1=CC=C(Cl)C=C1 CQPNKLNINBUUOM-JOCHJYFZSA-N 0.000 description 1
- REITVGIIZHFVGU-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[(2-methylpropan-2-yl)oxy]propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](COC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 REITVGIIZHFVGU-IBGZPJMESA-N 0.000 description 1
- LUGFCMICCJNLBC-VWLOTQADSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-6-[(2-methylpropan-2-yl)oxycarbonyl-propan-2-ylamino]hexanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCCN(C(C)C)C(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 LUGFCMICCJNLBC-VWLOTQADSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000377 degarelix acetate Drugs 0.000 description 1
- 230000032798 delamination Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 229940002006 firmagon Drugs 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C269/06—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C269/08—Separation; Purification; Stabilisation; Use of additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C29/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
- C07C29/74—Separation; Purification; Use of additives, e.g. for stabilisation
- C07C29/76—Separation; Purification; Use of additives, e.g. for stabilisation by physical treatment
- C07C29/78—Separation; Purification; Use of additives, e.g. for stabilisation by physical treatment by condensation or crystallisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C33/00—Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
- C07C33/18—Monohydroxylic alcohols containing only six-membered aromatic rings as cyclic part
- C07C33/24—Monohydroxylic alcohols containing only six-membered aromatic rings as cyclic part polycyclic without condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
- C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
- C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
- C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
- C07C2603/18—Fluorenes; Hydrogenated fluorenes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Crystallography & Structural Chemistry (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
本发明公开了一种Fmoc‑4‑Aph(Trt)‑OH的1/2三苯甲醇化物及其制备方法。Fmoc‑4‑Aph(Trt)‑OH是合成晚期前列腺癌治疗药物地加瑞克的起始物料之一,稳定性受温度影响很大,且在制备过程中的收率和纯度都难以保证。本发明以Fmoc‑Phe‑(4‑NH2)‑OH为底物,添加三苯基氯和吡啶后,使用乙酸乙酯和部分极性溶剂及非极性溶剂,通过重结晶的方法得到Fmoc‑4‑Aph(Trt)‑OH的1/2三苯甲醇化物。本发明制备得到的地加瑞克起始物料,高度去除原料杂质,保证了较高的纯度,且对热稳定,不易分解,对大规模工业化应用具有重要意义。
Description
技术领域
本发明涉及医药中间体合成领域领域,具体涉及一种Fmoc-4-Aph(Trt)-OH的1/2三苯甲醇化物及其制备方法。
背景技术
地加瑞克(Degraelix)是由辉凌(Ferring)公司研制开发的一种新的治疗晚期前列腺癌的药物。该药于2008年被FDA批准,商品名为Firmagon,是一种含有7个非天然氨基酸的线性十肽,肽序列为Ac-D-2-Na1-D-Phe(4-Cl)-D-3-Pal-Ser-4-Aph(L-Hor)-D-Aph(Cbm)-Leu-Lys-Pro-D-Ala-NH2。其中,Fmoc-4-Aph(Trt)-OH是合成地加瑞克的起始物料之一。现有技术中,该物料常采用重沉淀的方法制备得到。该物料本身对热不稳定,干燥和精制过程中容易分解,导致杂质。通过重沉淀方法得到的产物中,原料Fmoc-Phe-(4-NH2)-OH很难去除,在后续地加瑞克合成过程中会引入相关杂质,使得地加瑞克的纯化收率和纯度受到很大影响。除此之外,重沉淀方法制备得到的Fmoc-4-Aph(Trt)-OH静电较大,在实际生产中不利于操作,因此为了便于工业生产和扩大,亟需一种稳定性更好且受杂质和原料影响更低的地加瑞克合成起始物料。
发明内容
为了解决上述技术问题,提供一种稳定性更高,杂质含量更低,且便于工业化操作的地加瑞克起始物料Fmoc-4-Aph(Trt)-OH,本发明提供了一种Fmoc-4-Aph(Trt)-OH的1/2三苯甲醇化物及其制备方法。使用本方法制备得到的产物,在地加瑞克合成过程中能够减少杂质Fmoc-Phe-(4-NH2)-OH及其带来的影响。
本发明的第一个目的是提供一种Fmoc-4-Aph(Trt)-OH的1/2三苯甲醇化物,结构如下所示:
本发明的第二个目的是提供Fmoc-4-Aph(Trt)-OH的1/2三苯甲醇化物的制备方法,包括以下步骤:在有机溶剂中,Fmoc-Phe-(4-NH2)-OH与三苯基氯在吡啶类化合物存在的条件下反应,所得粗品经重结晶后得到所述Fmoc-4-Aph(Trt)-OH的1/2三苯甲醇化物。
进一步地,反应在20-50℃条件下进行。
优选地,有机溶剂为N,N-二甲基甲酰胺。
进一步地,混合原料后,滴加水使粗品固体析出。
进一步地,吡啶类化合物为吡啶或4-N,N-二甲基吡啶。
优选地,吡啶类化合物为吡啶。
进一步地,在重结晶之前,还包括将粗品溶解于溶剂中并浓缩的步骤,所述溶剂选自乙酸乙酯、乙酸甲酯、乙酸异丙酯和四氢呋喃中的一种或多种。
进一步地,粗品溶解后静置分层,将有机层浓缩并除去部分溶剂,加入重结晶溶剂。
进一步地,重结晶溶剂为极性溶剂与非极性溶剂的混合液。
进一步地,极性溶剂为乙酸乙酯、乙酸异丙酯、丙酮和甲醇中的一种或多种。
进一步地,非极性溶剂为石油醚、正庚烷和正己烷中的一种或多种。
进一步地,重结晶溶剂与粗品的比例为(5-10):1(mL:g)。
优选地,重结晶溶剂与粗品的比例为9.5:1(mL:g),在该比例下产物收率最高。
优选地,重结晶溶剂中极性溶剂与非极性溶剂的体积比为3.5:6。
进一步地,加入重结晶溶剂后,升温至50-100℃使产物溶解,然后降温至20-30℃析出晶体。
本发明的第三个目的是提供Fmoc-4-Aph(Trt)-OH的1/2三苯甲醇化物在地加瑞克合成中的应用。
本发明的有益效果:
以Fmoc-Phe-(4-NH2)-OH为原料,添加三苯基氯和吡啶后在DMF中反应,通过重结晶方法得到Fmoc-4-Aph(Trt)-OH的1/2三苯甲醇合物,该物料纯度高,对热稳定,干燥过程中不易分解,且易于储存;产物中原料杂质的含量低,降低了对后续合成的影响;流动性好,提升了生产中操作的简便性。
附图说明
图1是实施例1中产物Fmoc-4-Aph(Trt)-OH·1/2Trt-OH的XRD图
图2是实施例1中产物Fmoc-4-Aph(Trt)-OH·1/2Trt-OH的HPLC图;
图3是对比例1中产物Fmoc-4-Aph(Trt)-OH的HPLC图;
图4是实施例5中地加瑞克成品的HPLC图。
具体实施方式
下面结合附图和具体实施例对本发明作进一步说明,以使本领域的技术人员可以更好地理解本发明并能予以实施,但所举实施例不作为对本发明的限定。
实施例1
1L反应瓶中,加入DMF(N,N-二甲基甲酰胺),Fmoc-Phe-(4-NH2)-OH(150g,0.373mol),三苯基氯甲烷(TrtCl)(125g,0.448mol,1.2当量),搅拌下溶解;在10-20℃下,滴加吡啶;滴加完毕,在10-20℃搅拌反应4小时。在反应液中滴加水,有固体析出,抽滤得到固体;将该固体溶于乙酸乙酯中,静置分液,使用饱和食盐水洗涤有机层三次,用硫酸镁干燥;抽滤除去硫酸镁,减压(~0.09MPa)40℃下除去部分溶剂,得到浓缩液。加入甲醇,正庚烷,加热至完全溶解,缓慢降温至20-25℃,析出晶体,抽滤,滤饼在60℃真空干燥8小时,得到Fmoc-4-Aph(Trt)-OH的1/2三苯甲醇化物(图1),类白色固体,213g,收率为63%;其中原料Fmoc-Phe-(4-NH2)-OH含量为0.8%(图2)。
实施例2
1L反应瓶中,加入DMF(N,N-二甲基甲酰胺),Fmoc-Phe-(4-NH2)-OH(150g,0.373mol),三苯基氯甲烷(135g,0.485mol,1.3当量),搅拌下溶解;在10-20℃下,滴加吡啶;滴加完毕,在10-20℃搅拌反应4小时。在反应液中滴加水,有固体析出,抽滤得到固体;将该固体溶于乙酸乙酯中,静置分液,有机层用饱和食盐水洗3次,用硫酸镁干燥;抽滤除去硫酸镁,减压(~0.09MPa)40℃下除去部分溶剂,得到浓缩液。加入甲醇,正庚烷,加热溶清,缓慢降温至20-25℃,析出晶体,抽滤,滤饼在60℃真空干燥8小时,得到类白色固体,220g,收率为65%,其中原料Fmoc-Phe-(4-NH2)-OH含量为0.6%。
实施例3
1L反应瓶中,加入DMF(N,N-二甲基甲酰胺),Fmoc-Phe-(4-NH2)-OH(150g,0.373mol),三苯基氯甲烷(156g,0.56mol,1.5当量),搅拌下溶解;在10-20℃下,滴加吡啶;滴加完毕,在10-20℃搅拌反应4小时。在反应液中滴加水,有固体析出,抽滤得到固体;将该固体溶于乙酸乙酯中,静置分液,有机层用饱和食盐水洗3次,用硫酸镁干燥;抽滤除去硫酸镁,减压(~0.09MPa)40℃下除去部分溶剂,得到浓缩液。加入甲醇,正庚烷,加热溶清,缓慢降温至20-25℃,析出晶体,抽滤,滤饼在60℃真空干燥8小时,得到类白色固体,190g,收率为67%;其中原料Fmoc-Phe-(4-NH2)-OH含量为1.0%。
实施例4
1L反应瓶中,加入DMF(N,N-二甲基甲酰胺),Fmoc-Phe-(4-NH2)-OH(150g,0.373mol),三苯基氯甲烷(135g,0.485mol,1.3当量),搅拌下溶解;在10-20℃下,滴加吡啶;滴加完毕,在10-20℃搅拌反应4小时。在反应液中滴加水,有固体析出,抽滤得到固体;将该固体溶于乙酸乙酯中,静置分液,有机层用饱和食盐水洗3次,用硫酸镁干燥;抽滤除去硫酸镁,减压(~0.09MPa)40℃下除去部分溶剂,得到浓缩液。加入丙酮,正庚烷,加热溶清,缓慢降温至20-25℃,析出晶体,抽滤,滤饼在60℃真空干燥8小时,得到类白色固体,220g,收率为65%,其中原料Fmoc-Phe-(4-NH2)-OH的含量为1.1%。
实施例5
以Rink Amide AM树脂为固相载体,DMF为溶剂,按照肽序列从C端到N端依次缩合Fmoc-D-Ala-OH、Fmoc-Pro-OH、Fmoc-Lys(iPr,Boc)-OH、Fmoc-Leu-OH、Fmoc-D-4-Aph(Cbm)-OH、Fmoc-4-Aph(Trt)-OH、Fmoc-Ser(tBu)-OH、Fmoc-D-3-Pal-OH、Fmoc-D-Phe-(4-Cl)-OH、Fmoc-D-2-Nal-OH,脱除Fmoc保护,N-乙酰化,然后脱除Trt保护上L-Hor,最后用TFA脱保护和脱树脂,得到粗肽。粗肽通过高效液相色谱柱过柱纯化,转盐,浓缩,冻干得到成品醋酸地加瑞克。在这一过程中,使用实施例1制备得到的Fmoc-4-Aph(Trt)-OH·1/2Trt-OH为起始物料代替Fmoc-4-Aph(Trt)-OH,通过后续纯化步骤,得到的地加瑞克成品收率60%,纯度高于99%(图4)。
对比例1
1L反应瓶中,加入DMF(N,N-二甲基甲酰胺),Fmoc-Phe-(4-NH2)-OH(150g,0.373mol),三苯基氯甲烷(135g,0.485mol,1.3equiv),搅拌下溶解;在10-20℃下,滴加吡啶;滴加完毕,在10-20℃搅拌反应4小时。在反应液中滴加水,有固体析出,抽滤得到固体;将该固体溶于乙酸乙酯中,静置分液,有机层用饱和食盐水洗3次,用硫酸镁干燥;抽滤除去硫酸镁,减压(~0.09MPa)40℃下除去部分溶剂,得到浓缩液。滴入正庚烷中,有固体析出,滴完在该温度搅拌2小时,抽滤,得到固体;再次用乙酸乙酯溶解,滴入正庚烷中,有固体析出,滴完在该温度搅拌2小时,抽滤,得到固体,在40℃干燥8小时,得到类白色固体,Fmoc-4-Aph(Trt)-OH,140g,收率为58%,其中原料Fmoc-Phe-(4-NH2)-OH的含量为8.0%(图3)。
以上所述实施例仅是为充分说明本发明而所举的较佳的实施例,本发明的保护范围不限于此。本技术领域的技术人员在本发明基础上所作的等同替代或变换,均在本发明的保护范围之内。本发明的保护范围以权利要求书为准。
Claims (10)
1.一种Fmoc-4-Aph(Trt)-OH的1/2三苯甲醇化物,结构式如下所示:
2.一种Fmoc-4-Aph(Trt)-OH的1/2三苯甲醇化物的制备方法,其特征在于,包括以下步骤:在有机溶剂中,Fmoc-Phe-(4-NH2)-OH与三苯基氯在吡啶类化合物存在的条件下反应,所得粗品经重结晶后得到所述Fmoc-4-Aph(Trt)-OH的1/2三苯甲醇化物。
3.根据权利要求2所述的方法,其特征在于:所述吡啶类化合物为吡啶或4-N,N-二甲基吡啶。
4.根据权利要求2所述的方法,其特征在于:在重结晶之前,还包括将所述粗品溶解于溶剂中并浓缩的步骤,所述溶剂选自乙酸乙酯、乙酸甲酯、乙酸异丙酯和四氢呋喃中的一种或多种。
5.根据权利要求2所述的方法,其特征在于:重结晶溶剂为极性溶剂与非极性溶剂的混合液。
6.根据权利要求5所述的方法,其特征在于:所述极性溶剂为乙酸乙酯、乙酸异丙酯、丙酮和甲醇中的一种或多种。
7.根据权利要求5所述的方法,其特征在于:所述非极性溶剂为石油醚、正庚烷和正己烷中的一种或多种。
8.根据权利要求2或5所述的方法,其特征在于:重结晶溶剂与粗品的比例为(5-10):1(mL:g)。
9.根据权利要求2所述的方法,其特征在于:加入重结晶溶剂后,升温至50-100℃使产物溶解,然后降温至20-30℃析出晶体。
10.如权利要求1所述的Fmoc-4-Aph(Trt)-OH的1/2三苯甲醇化物在地加瑞克合成中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311299760.2A CN117362199A (zh) | 2023-10-09 | 2023-10-09 | 一种Fmoc-4-Aph(Trt)-OH的1/2三苯甲醇化物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311299760.2A CN117362199A (zh) | 2023-10-09 | 2023-10-09 | 一种Fmoc-4-Aph(Trt)-OH的1/2三苯甲醇化物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117362199A true CN117362199A (zh) | 2024-01-09 |
Family
ID=89393930
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311299760.2A Pending CN117362199A (zh) | 2023-10-09 | 2023-10-09 | 一种Fmoc-4-Aph(Trt)-OH的1/2三苯甲醇化物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117362199A (zh) |
-
2023
- 2023-10-09 CN CN202311299760.2A patent/CN117362199A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11952341B2 (en) | Method of preparing high chiral purity lactam intermediate and brivaracetam | |
CN113999142B (zh) | 一种手性N-Boc-反式-1,2-环己二胺的制备方法 | |
CN103864748B (zh) | 一种4-氯甲基-5-甲基-1,3-二氧杂环戊烯-2-酮的纯化方法 | |
CN114315538B (zh) | 一种作为多肽液相合成载体的苄醇酚醚类化合物及其制备方法与应用 | |
CN108395381B (zh) | 1,4-二氨基蒽醌隐色体的合成方法 | |
CN117362199A (zh) | 一种Fmoc-4-Aph(Trt)-OH的1/2三苯甲醇化物及其制备方法 | |
CN114409566B (zh) | 一种碘佛醇水解物的制备方法 | |
CN111116430B (zh) | 一种牛磺酸钠的制备方法 | |
CN112645799B (zh) | 一种间苯二酚的后处理工艺 | |
CN111072450B (zh) | 一种烯丙醇类衍生物的合成方法 | |
CN111454231B (zh) | 一种合成2-氨基-5-硝基噻唑的方法 | |
CN107216332A (zh) | 叔丁基‑7‑羟甲基‑7,8‑二氢4h吡唑并二氮杂卓5(6h)甲酸基酯的合成方法 | |
CN111116503A (zh) | 一种高纯度米卡芬净中间体的制备方法 | |
CN112645889A (zh) | 一种法匹拉韦的精制方法 | |
CN111533656A (zh) | 一种4-甲氧基-3-氧代丁酸叔丁酯的合成方法 | |
CN111217709A (zh) | 一种(1-氟环丙基)甲胺盐酸盐的制备方法 | |
CN114195684B (zh) | 一种氨基保护基n-取代手性氨基酸的合成方法 | |
CN114573557B (zh) | 一种奥特康唑的制备方法 | |
CN111875577B (zh) | 一种r-碳酸丙烯酯的制备方法 | |
CN118063295A (zh) | 一种聚多卡醇的纯化方法 | |
CN117756622A (zh) | 一种沙库巴曲关键中间体的制备方法 | |
CN116621789A (zh) | 一种(4s)-3-[2-[[芴甲氧羰基]氨基]乙酰基]-2,2-二甲基-4-恶唑烷羧酸的合成方法 | |
CN115536494A (zh) | 1-(4-溴苯基)-1,4-丁二醇的合成方法 | |
CN117285600A (zh) | 一种醋酸加尼瑞克的合成方法 | |
CN114195737A (zh) | 5-(苯基)-1,3,2,4-二氧杂噻唑2-氧化物及其制备 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |